PhRMA renews pharmacy benefits manager campaign as Congressional scrutiny heats up

Roughly a month after announcing plans to merge several units under Sumitomo Pharma America this July, the drugmaker is making cuts in Massachusetts.

Sumitomo Pharma America Holdings and Sumitomo Pharma Oncology have announced a combined 122 layoffs to take effect June 30, according to Massachusetts’ WARN system. Another Sumitomo unit, Sunovion Pharmaceuticals, will make 101 cuts.

Sumitomo announced in early April that it was combining Sunovion, Sumitomo Pharma Oncology, Sumitomo Pharma America Holdings, Sumitovant Biopharma, Myovant Sciences, Urovant Sciences and Enzyvant Therapeutics to form Sumitomo Pharma America. Sumitomo said at the time that the combined company would house a “diverse portfolio of commercialized products and robust pipeline of early- to late-stage assets” across the central nervous system, oncology, urology, women’s health, and cell and gene therapies.

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 167,200+ biopharma pros reading Endpoints daily — and it’s free.

Biden’s Physical Results; Weight Loss Implant Tested; Richard Lewis Dies

Note that some links may require registration or subscription. President Joe Biden “continues to be fit for duty,” his doctor said after Biden’s annual physical

March 1, 2024

EMA-endorsed statement targets Covid-19 vaccine misinformation – Pharmaceutical Technology

False information about Covid-19 vaccines includes the frequency and severity of certain side effects. There are also unfounded claims that the vaccines led to excess

July 6, 2023

Manufacturing roundup: Andelyn Biosciences opens new facility in Ohio; Novo warns of Ozempic counterfeit

Andelyn Biosciences, a cell and gene therapy CDMO, has opened a new manufacturing headquarters in Columbus, OH. The new 180,000-square-foot facility is home to Andelyn’s

June 23, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.